Abstract 1199P
Background
NEN are a group of heterogeneous malignancies that most commonly arise in the GEP tract. Usually > 20% Ki-67 NEN, including both well and poorly differentiated, are treated with chemotherapy (CT) but the schedule and duration is debated and no evidence about a maintenance therapy exists.
Methods
MAVERIC is a randomized, multicentric, phase II trial. Patients (pts) with well/moderately or poorly differentiated mNEN from GEP or lung primary sites with Ki-67 between 20% and 55% in response after a first -line (1L) CT were randomized with a 2:1 ratio to maintenance therapy with everolimus 10 mg day or to observation until progression or treatment intolerance. Randomization was done using a centralized web-based system. The primary endpoint was progression free survival (PFS) and the secondary endpoints were overall survival (OS) and safety. The study design was formally non-comparative.
Results
Of 30 patients enrolled between 2015 and 2022 in 5 centers, 20 were randomized to everolimus and 10 to observation; 29 resulted eligible for the analysis. 52% had a GEP and 48% a pulmonary primary site. The median follow-up was 30.3 mo. Median PFS was longer for the experimental arm (1.8 mo vs. 11.4 mo; p=0.022). Median OS was 38.3 and 38.2 mo for the experimental and control arms, respectively (p=0.43). In the experimental arm, G3 adverse events (AEs) occurred in 55% of pts (most commonly mucositis/stomatitis (27.7%) and neutropenia (27.7%)). No G4 AEs occurred. 65% of pts required a dose reduction and 2 pts discontinued treatment due to AEs.
Conclusions
This study may suggest a role for everolimus as a maintenance therapy following 1L CT in selected pts with high-grade GEP or lung NEN with Ki67 between 20% and 55%. Homogeneous prospective studies are warranted to validate this hypothesis.
Clinical trial identification
EudraCT n. 2014-003951-72.
Editorial acknowledgement
Legal entity responsible for the study
Lorenzo Antonuzzo.
Funding
Has not received any funding.
Disclosure
L. Antonuzzo: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Roche, Lilly, BMS, MSD, Merck, Amgen. F. Spada: Financial Interests, Personal, Invited Speaker: Advanced Accelerator Applications, SAS SPA; Financial Interests, Personal, Writing Engagement: Ipsen, Merck, Advanced Accelerator Applications; Non-Financial Interests, Project Lead, Coordinator of neuroendocrine neoplasms guidelines: AIOM (Italian Association Of Medical Oncology); Non-Financial Interests, Leadership Role, I am member of Scientific Board and lead of neuroendocrine Neoplasms Guidelines: ITANET (Italian Association Of Medical Oncology). N. Fazio: Financial Interests, Personal, Advisory Board: Novartis, Merck, AAA, Hutchinson MediPharma, MSD; Financial Interests, Personal, Invited Speaker: AAA, Merck; Financial Interests, Institutional, Local PI: Astellas, MSD, BeiGene, Incyte, Nucana, Ipsen, 4SC, Fibrogen; Financial Interests, Institutional, Research Grant: IPSEN, AAA, Merck; Non-Financial Interests, Other, Steering committee: SPARC Europe; Non-Financial Interests, Member of Board of Directors: ENETS; Non-Financial Interests, Other, Member of the GI and NET Faculties: ESMO; Non-Financial Interests, Other, Internal reviewer of NET guidelines: AIOM. All other authors have declared no conflicts of interest.
Resources from the same session
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1169P - Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Presenter: Martha Estefania Vázquez-Cruz
Session: Poster session 13